Absorption, Distribution, Metabolism and Excretion Pharmacogenomics of Drugs of Abuse
Pharmacogenomics February 1, 2011 DOI: 10.2217/pgs.10.171 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Pharmacology Alfentanil Hydrocodone Oxycodone Pharmacokinetics Opioid Drug metabolism Dextromethorphan Methadone Cyp2d6 |
| Citations | 107 |
| Key findings | The metabolism of frequently abused drugs and other xenobiotics depends on specific isoenzymes, and understanding these pathways is crucial for predicting interactions, assessing toxicity, and interpreting drug tests. |
Abstract
Pharmacologic and toxic effects of xenobiotics, such as drugs of abuse, depend on the genotype and phenotype of an individual, and conversely on the isoenzymes involved in their metabolism and transport. The current knowledge of such isoenzymes of frequently abused therapeutics such as opioids (oxycodone, hydrocodone, methadone, fentanyl, buprenorphine, tramadol, heroin, morphine and codeine), anesthetics (γ-hydroxybutyric acid, propofol, ketamine and phencyclidine) and cognitive enhancers (methylphenidate and modafinil), and some important plant-derived hallucinogens (lysergide, salvinorin A, psilocybin and psilocin), as well as of nicotine in humans are summarized in this article. The isoenzymes (e.g., cytochrome P450, glucuronyltransferases, esterases and reductases) involved in the metabolism of drugs and some pharmacokinetic data are discussed. The relevance of such data is discussed for predicting possible interactions with other xenobiotics, understanding pharmacokinetic behavior and pharmacogenomic variations, assessing toxic risks, developing suitable toxicological analysis procedures, and finally for interpretating drug testing results.
Citations in the library
Cited by 7
- DARK Classics in Chemical Neuroscience: Psilocybin ACS Chemical Neuroscience June 29, 2018
- Psychedelic Cognition—The Unreached Frontier of Psychedelic Science Frontiers in Neuroscience March 15, 2022
- Considering the nocebo effect in the psychedelic discourse Journal of Psychedelic Studies May 10, 2024
- Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy. Molecular biotechnology 2025
- Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing. British Journal of Clinical Pharmacology June 16, 2025
and 2 more in the library
Cites 18
- The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate British Journal of Pharmacology June 1, 1983
- Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences September 3, 2002
- The pharmacology of psilocybin Addiction Biology October 1, 2002
- The Pharmacology of Lysergic Acid Diethylamide: A Review CNS Neuroscience & Therapeutics November 11, 2008
- Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives Therapeutic Drug Monitoring April 1, 2002
and 13 more in the library